Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) – Equities researchers at HC Wainwright upped their Q3 2026 EPS estimates for shares of Celldex Therapeutics in a research note issued on Friday, August 7th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will post earnings of ($1.05) per share for the quarter, up from their previous forecast of ($1.12). HC Wainwright also issued estimates for Celldex Therapeutics’ Q4 2026 earnings at ($1.08) EPS, FY2026 earnings at ($4.23) EPS and FY2027 earnings at ($4.49) EPS. Get Celldex Therapeutics alerts:Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. See AlsoReceive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.